This article is about how some things are going up and some things are going down in the world of money and businesses. Crude oil, which is a type of fuel, is going up in price. Instil Bio, a company that is working on special medicines, is going down because their shares (which is like owning part of the company) are not doing well. Read from source...

from Crude Oil surges over 1% to Instil Bio shares plunge. The title misleadingly implies that the plunge of Instil Bio shares is directly related to the surge of Crude Oil. There is no clear evidence or logical argument provided in the article to establish this connection. The article is lackluster and weak in terms of providing insightful analysis and valuable information to the readers.

Neutral.

### NICK:
Article Sentiment: Neutral. The article discusses the rise in crude oil prices and the drop in Instil Bio shares. It doesn't show any specific sentiment towards the market, as it's just reporting the facts.

Crude oil futures, shares of Instil Bio and Ascendis Pharma, NuCana and Nuvalent stocks.
1. Crude oil futures: Crude oil prices have surged over 1%, indicating a potential increase in oil prices. This could impact energy-related stocks positively, and investors can consider investing in crude oil futures.
Risk: Fluctuations in oil prices can cause sudden losses, and investors should be prepared for potential losses.
2. Instil Bio (TIL): Instil Bio shares have plunged 25% due to the announcement of the global registrational strategy for the PD-1 bispecific antibody SYN-2510/IMM2510. Investors should avoid investing in Instil Bio shares until the situation improves.
Risk: Further decline in the stock price can cause substantial losses.
3. Ascendis Pharma (ASND): Ascendis Pharma shares surged 17% after the company announced the topline data from its pivotal approach trial of Transcon CNP. Investors can consider investing in Ascendis Pharma shares.
Risk: Investors should monitor the progress of the clinical trial and potential regulatory approvals before investing.
4. NuCana (NCNA): NuCana shares shot up 151% after the company announced final data from the Phase 2 NuTide:701 study. Investors can consider investing in NuCana shares.
Risk: Investors should monitor the progress of the clinical trial and potential regulatory approvals before investing.
5. Nuvalent (NUVL): Nuvalent shares were up, gaining 28% after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs. Investors can consider investing in Nuvalent shares.
Risk: Investors should monitor the progress of the clinical trial and potential regulatory approvals before investing.